Asthma Biologic Omalizumab May Benefit AGS Patients
Omalizumab (Xolair) reduced reaction severity and eliminated the need for emergency epinephrine following food exposure.
Omalizumab (Xolair) reduced reaction severity and eliminated the need for emergency epinephrine following food exposure.
A recent cruise ship outbreak of the Andes strain underscores the potential for silent spread and severe respiratory complications in travel networks.
Approximately 40% of insurance requests for pediatric asthma biologic therapies are denied, with approvals taking more than a month on average.
Breathing fine particles and wildfire pollution during the second and third trimesters may increase asthma risks for young children.